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Negative relationship between plasma high-density lipoprotein (HDL) levels and risk of car-
diovascular disease (CVD) is a firmly established medical fact, but attempts to reproduce
protective properties of HDL by pharmacologically elevating HDL levels were mostly unsuc-
cessful. This conundrum presents a fundamental question: were the approaches used to
raise HDL flawed or the protective effects of HDL are an epiphenomenon? Recent attempts
to elevate plasma HDL were universally based on reducing HDL catabolism by blocking
reverse cholesterol transport (RCT). Here, we argue that this mode of HDL elevation may
be mechanistically different to natural mechanisms and thus be counterproductive. We
further argue that independently of whether HDL is a driving force or a surrogate mea-
sure of the rate of RCT, approaches aimed at increasing HDL supply, rather than reducing
its catabolism, would be most beneficial for speeding up RCT and improving protection
against CVD.
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A HERO?
Plasma concentration of high-density lipoprotein (HDL) strongly
inversely correlates with risk of cardiovascular disease (CVD). This
was first convincingly demonstrated in the Framingham Heart
Study (1) and confirmed in several large reputable studies (2). Not
a single large study presented any evidence contradicting this con-
clusion or raised doubts in its validity. Inverse relationship between
plasma levels of HDL and risk of CVD is as much a medical fact
as anything can possibly be.
Considering that the strength and consistency of this relation-
ship is similar to the positive association between low density
lipoprotein (LDL) and risk of CVD, and tremendous success
of pharmacological treatment of high LDL levels, much effort
was applied to repeating the success of statins in a treatment
aimed at elevating the HDL. Elevating HDL by lifestyle modifi-
cations, such as exercise or dietary intervention, produced pos-
itive outcomes, but did not prove the causative role or even a
contribution of HDL elevation to their protective effects: the
magnitude of changes of HDL level was modest and, more
importantly, these interventions affected many other CVD risk
factors. Similarly, pharmacological interventions not specifically
designed to raise HDL, but associated with higher HDL lev-
els, such as fibrates, were beneficial, but for most of them ele-
vated HDL was only one of the several beneficial effects. A drug
specifically designed to elevate HDL level was required to deci-
sively test the hypothesis of benefits of elevating HDL. Several
approaches were proposed [for recent reviews see Ref. (3, 4)],
and several of them, primarily cholesteryl ester transfer pro-
tein (CETP) inhibitors, underwent large-scale phase III clinical
trials.
A MIRAGE?
The outcome of the trial of first CETP inhibitor, Trocetrapib,
was negative: torcetrapib significantly elevated HDL-C levels and
reduced LDL-C levels, but total and cardiovascular mortality and
morbidity increased (5). The trial of another CETP inhibitor,
Dalcetrapib, produced similar outcomes: significant elevation of
plasma HDL-C with no effect on cardiovascular mortality and
morbidity (6). A genetic study analyzing an association between
elevation of HDL-C due to polymorphism in endothelial lipase
and risk of myocardial infarction also found no beneficial effect
of higher HDL-C levels (7). A trial of niacin, although under-
powered to see the effects of actual changes in HDL-C, also
suggested a similar conclusion that elevation of HDL-C was not
associated with better cardiovascular outcomes (8). What are
the possible explanations of an apparent contradiction between
clearly cardioprotective effects of naturally occurring high levels
of HDL-C, and no such effects of pharmacological elevation of
HDL-C?
OFF-TARGET EFFECTS
The first explanation brought forward for failure of torcetrapib
was its off-target effects. Indeed, patients in the experimental arm
of ILLUMINATE study had slightly elevated blood pressure (5).
This phenomenon was reproduced in rats, a species that does not
express CETP, thus it was clearly an off-target effect (9). How-
ever, in addition to a 25% increase in mortality that was observed,
this putative off-target effect should also account for lack of 25%
decrease in mortality that should have occurred due to lowering
of LDL-C level, which did not eventuate, and a 75% decrease in
mortality due to elevation of HDL-C, which also did not even-
tuate. Thus, an off-target effect(s) should have been responsible
for about a 125% increase of mortality to offset the expected
beneficial effects of treatment if the underlying hypothesis was
correct; clearly, a highly unlikely possibility. Finally, another CETP
inhibitor, dalcetrapib, did not cause blood pressure elevation, but
still did not reduce cardiovascular mortality (6). Overall, given
excellent safety record of torcetrapib (10), it is unlikely that failure
of CETP inhibitors to improve cardiovascular outcomes was due
to off-target effects.
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HDL FUNCTIONALITY
Another explanation was that CETP inhibitors elevate plasma level
of HDL-C, but impair functionality of HDL. Inhibition of CETP
precludes exchange of cholesteryl esters (CE) and triglycerides
(TG) between HDL and apoB-containing lipoproteins (mainly
Very Low Density Lipoprotein, VLDL) resulting in reduced catab-
olism of HDL and accumulation of larger TG-rich HDL parti-
cles (11). HDL was implicated in many anti-atherogenic activi-
ties, and changes in HDL composition or size may affect some
aspects of HDL functionality, at least in vitro. However, when
tested in animals (12) and humans (13–15), this suggestion was
not confirmed: HDL functionality, at least toward its two most
important functions, reverse cholesterol transport (RCT) and
anti-inflammatory properties, was unaffected by inhibition of
CETP. Anti-oxidation function of HDL was also unaffected in
subjects with CETP deficiency (16). Overall, no evidence was pro-
duced to support a hypothesis that failure of CETP inhibitors
to improve cardiovascular outcomes was due to impaired HDL
functionality.
METABOLIC CONTEXT
Initial steps of RCT, cholesterol efflux, formation of nascent HDL
particles, and early steps of HDL remodeling are very similar in
humans and animals. However, late steps of RCT are different:
delivery of CE to the liver may occur via direct RCT pathway,
selective uptake of CE from HDL by hepatocyte through HDL
receptor SR-B1, or indirect RCT pathway, after transfer of CE to
VLDL/LDL and uptake of LDL by hepatocyte LDL receptor. The
ratio between these two pathways is mainly driven by the activity
of CETP and differs between humans and animals.
Preclinical studies supporting beneficial effects of CETP
inhibitors were done in rabbits, a species that, like humans,
expresses CETP and is susceptible to diet-induced atherosclero-
sis (17). HDL metabolism in rabbits, however, is different from
that in humans (18). In this regard, it is interesting to compare
the effects of CETP deficiency/inhibition in species with different
CETP activities (12). Mice do not express CETP, but CETP may be
introduced in mice systemically following adenovirus-mediated
transfection. Moderate overexpression of CETP in mice did not
affect HDL-C or LDL-C levels, but increased the rate of RCT; the
effect was blocked by torcetrapib (12). The explanation is likely
that supplementation of natural direct pathway with additional
indirect pathway resulted in overall higher rates of RCT, and CETP
inhibition in this context had an adverse effect on the overall rate
of RCT (Figure 1A). Hamsters express CETP, but activity is less
than in humans and HDL-C levels are fivefold higher than in
humans. Inhibition of CETP in this context resulted in further
increase in plasma HDL-C levels and increased the overall rate of
RCT (12). The explanation is likely that inhibition of relatively
minor indirect pathway and stimulation (through higher HDL-C
levels) of the predominant direct pathway resulted in overall faster
RCT (Figure 1B). Apparently, in hamsters, liver had sufficient lev-
els of SR-B1 to handle modest amount of additional cholesterol
delivered through direct pathway. In humans, CETP activity is
high, HDL-C levels are low, and indirect pathway accounts for
almost 90% of RCT traffic (19). CETP inhibition would block
indirect RCT pathway and increase direct RCT pathway, however,
FIGURE 1 |The proposed effect of CETP inhibition on reverse
cholesterol transport in mice (A), hamsters (B), humans (C), and
rabbits (D). (A) In mice, the only pathway of delivery of HDL-C to liver is
selective uptake of HDL cholesteryl esters via scavenger receptor type B1
(SR-B1). Introduction of CETP does not affect this pathway, but introduce an
additional pathway via apoB-containing lipoproteins and LDL receptors
overall increasing RCT. Inhibition of heterologous CETP by Torcetrapib
removes this additional pathway and the net effect on RCT is negative.
(B) In hamsters, the selective uptake of HDL cholesteryl esters by liver is a
predominant pathway of reverse cholesterol transport, but the pathway via
apoB-containing lipoproteins is contributing. Torcetrapib inhibits the latter
leading to increased HDL-C levels that stimulate macrophage cholesterol
efflux; the net effect is enhanced reverse cholesterol transport. (C) In
humans, delivery of HDL cholesterol via CETP and LDL receptors is a major
pathway with smaller contribution of direct uptake of HDL cholesteryl
esters by liver. Statins stimulate the former pathway by increasing
abundance of LDL receptors, torcetrapib inhibits it by blocking CETP.
Torcetrapib increases HDL-C, which is associated with an increase in
cholesterol efflux and further reduces VLDL/LDL associated with reduced
cholesterol efflux. The reverse cholesterol transport under torcetrapib
treatment in humans would be a balance between two opposing influences
and the net effect is uncertain, likely neutral. (D) In rabbits, delivery of HDL
cholesterol via CETP and LDL receptors is also a major pathway with
minimal contribution of direct uptake of HDL cholesteryl esters by liver.
Torcetrapib increases HDL-C, which is associated with an increase in
cholesterol efflux, but does not decrease VLDL/LDL levels allowing for
transfer of free cholesterol to these apolipoproteins in the course of RCT.
The overall balance of reverse cholesterol transport under torcetrapib
treatment in rabbits appears to be positive.
the benefits would depend on a balance between the two and on
how much of additional cholesterol flow through direct pathway
can be handled by liver (Figure 1C). Does human liver have, or
can attain sufficient levels of CLA-1 (human analog of SR-B1) to
process sharply increased flow through direct RCT pathway or it
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gets saturated? Several studies investigated the effect of torcetrapib
on fecal cholesterol excretion, the endpoint of RCT, and found no
change. In rabbits, CETP activity is triple that of humans and
HDL-C level is 15% of that in humans (18). The rate of RCT in
rabbits and the effects of CETP inhibitors on this rate were not
studied, but the effects on development atherosclerosis were ben-
eficial (17) implying that RCT rate was also elevated (Figure 1D).
Interestingly, although torcetrapib caused elevation of HDL-C in
rabbits, it was still about half of that in normolipidemic humans
and less than a third of what was observed in patients treated with
torcetrapib (5), in addition there was no reduction in LDL-C. Per-
haps, HDL levels in rabbits, in contrast to humans, are still below
saturation of the direct pathway, and rabbits, but not humans, can
handle a switch from indirect to direct RCT. One conclusion is,
however, clear: the overall effect of CETP inhibition is a balance
between inhibition of the indirect pathway and stimulation of the
direct pathway of RCT and this balance is greatly influenced by
metabolic context.
DRUG INTERACTION
It is important to recognize that in all clinical trials of CETP
inhibitors, patients in both arms of the study were receiving statins.
Statins inhibit cholesterol biosynthesis in liver causing sharp ele-
vation of the expression of hepatocyte LDL receptors leading to
increased catabolic rate of LDL and lowering plasma LDL-C level.
Uptake of LDL, however, is also a key step of indirect RCT path-
way delivering to liver HDL-derived cholesterol after its transfer
to VLDL/LDL. By increasing LDL uptake, statins would stimulate
indirect RCT pathway, the very same pathway that is inhibited
by CETP inhibitors (Figure 1C). Thus, statins and CETP inhibi-
tion have opposing effects on indirect RCT pathway. Furthermore,
VLDL/LDL plays an important role in the initial stages of RCT.
Most of cellular free cholesterol taken up by HDL ends up in
VLDL/LDL prior to esterification, as VLDL/LDL provides a pool
with much bigger capacity to hold free cholesterol before rela-
tively slow process of esterification converts cholesterol into esters
(20). This finding gave rise to the “shuttle” and “sink” hypothesis
(21) also supported by findings that cholesterol efflux to plasma
devoid of apoB-containing lipoproteins is much slower and that
the availability of apoB-containing lipoproteins may become rate
limiting in RCT when HDL-C level are significantly increased (22).
Interestingly, humans are the only species where CETP inhibition
caused reduction of VLDL/LDL levels (Figure 1), which could
also contribute to reductions of overall rate of RCT. In this con-
text, combining CETP inhibitors and statins may have detrimental
effect on the actions of both drugs.
AWITNESS?
Another possible explanation for the contradiction between
inverse relationship between plasma HDL levels and CVD and
negative outcomes of the clinical trials aimed at raising HDL is
that HDL is not a causative agent at all, but is a biomarker.
Reverse cholesterol transport is essentially a flow taking exces-
sive cholesterol from peripheral cells and tissues to liver for either
repackaging or excretion (23). In this context, HDL is an interme-
diate in this chain of reactions and plasma level of HDL may be
a reflection, rather than a driving force of the flow. Static level of
an intermediate, however, is a good marker of the flow rate if the
rate-limiting step is located before a particular intermediate, e.g.,
generation of HDL through cholesterol efflux. If the rate-limiting
step is located after this step, e.g., catabolism or remodeling of
HDL, then high level of the intermediate may be caused by its
inability to proceed along the pathway and indicates a retarded
rather than accelerated flow. In this context, attempts to elevate
HDL-C levels by inhibiting its remodeling, as it happened with
CETP inhibitors, niacin and polymorphism in endothelial lipase,
may reduce the flow through RCT and are counterproductive.
Approaches aimed at increasing supply of HDL, such as infusion
of rHDL, may therefore be more productive in increasing RCT
and higher levels of HDL achieved in this manner may be more
reflective of RCT flow rate.
Furthermore, in the context of “flow” concept, static plasma
HDL level may also reflect the rate of HDL formation, and there-
fore, the activity of the main cholesterol transporter responsible
for the HDL formation, ABCA1 (24). ABCA1, however, is not only
a key molecule in HDL formation, but also a key regulator of cho-
lesterol efflux, a process removing excessive cholesterol from cells,
including vascular cells. Consequently, HDL-C may be a true bio-
marker of ABCA1 activity, and it is ABCA1 activity that protects
against cholesterol accumulation and risk of CVD, and ABCA1
should be a target for treatment, rather than HDL level.
Admittedly, the role of HDL in RCT is not the only atheropro-
tective function of HDL. HDL also displays anti-inflammatory,
anti-oxidant, anti-platelet, anti-apoptotic, and other properties
that should be beneficial for reducing cardiovascular risk [for
review, see Ref. (25)]. The dependence of these properties on the
role of HDL in cellular cholesterol metabolism and systemic RCT
is unclear, as is the contribution of each of these properties to
overall cardiovascular protection associated with higher HDL lev-
els. However, assuming that these properties contribute to overall
atheroprotection and are independent of cholesterol metabolism,
it is possible that raising HDL by any means would be beneficial,
but so far there is little evidence that this is the case.
THE LIGHT AT THE END OF THE TUNNEL OR THE HEADLAMP
OF AN ONCOMING TRAIN?
Negative outcomes of large clinical trials of HDL-targeted ther-
apy prompted several large pharmaceutical companies to abandon
further attempts to develop approaches to elevate plasma HDL
and declare the death of HDL Therapy. However, the negative
relationship between naturally occurring plasma HDL-C levels
and risk of CVD has never been challenged and the issue is
whether pharmacological elevation of plasma HDL would have
the same protective effect. The obvious question is then whether
the mechanisms responsible for naturally high HDL levels were
the same mechanisms targeted in attempts to raise HDL pharma-
cologically. Both mechanisms are grossly under investigated, but
within this limitation the answer is probably not. Targeting HDL
catabolism increases HDL-C levels, but at the same time retards
RCT and may have the outcome opposite to what was intended.
Alternative approaches, such as increased supply of HDL, may be
more appropriate. Thus, the outcomes of several human trials of
rHDL infusion were encouraging (26, 27). RVX-208, an epigenetic
inducer of biosynthesis of apolipoprotein A-I, produced positive

























































Sviridov Targeting HDL for therapy
outcomes in preclinical studies (28), but reportedly was toxic in
humans. Negative outcomes of clinical trials created understand-
able skepticism, but there are too many questions about validity of
the approaches tested in these trials to provide a credible challenge
to the idea of HDL-targeted therapy. With better understanding
of how HDL and RCT protect against CVD, the last word in HDL
story is yet to be written.
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